Introduction
Neuroblastoma, a cancer of childhood, arises from sympathoadrenal progenitor cells and exhibits heterogeneity in responses to neurotrophic factors. The prognosis family, CNTF signals by complexing with an alpha coreceptor (CNTFRα), LIFRβ, and GP130 [7] . CNTF promotes the survival of sympathetic, sensory, motor, retinal, and hippocampal neurons [8] [9] [10] . Furthermore, CNTF induces astrocytic differentiation of O2A precursors and causes profound weight loss when injected systemically [11, 12] . In mature neurons, CNTFRα is ubiquitously expressed, yet the expression of the ligand, CNTF, is more restricted [13] . Although chicken CNTF can be secreted, murine and human CNTF are not [14] . Thus, in mammals, CNTF accumulates intracellularly in myelinating Schwann cells and astrocytes, suggesting that it is released by injury to support neural regeneration.
Previously, a mouse model of neuroblastoma, generated by targeting the expression of MYCN to the neural crest lineage using the rat tyrosine hydroxylase (TH) promoter [15] , demonstrated that the overexpression of MYCN is sufficient to cause neuroblastoma; this model has been useful in studying the earliest cellular and molecular changes that may occur in the genesis of MYCNamplified neuroblastoma [16, 17] . One hundred percent of 129/SvJ mice homozygous for the TH-MYCN transgene develop tumors by 6.5 weeks of age. These tumors show typical histopathological features of human neuroblastoma [18] , as well as genetic aberrations similar to those found in the human disease [19, 20] . The process by which these tumors develop at sites where sympathoadrenal progenitors coalesce is not well understood. In addition, the responsiveness of TH-MYCN tumor cells to growth factors has not been examined in detail. By following the formation of tumors in homozygous TH-MYCN mice, we were able to capture transformed cells prior to the formation of large, vascularized tumors in order to determine the responsiveness of cells to neurotrophic factors. We report that these cells fail to respond to neurotrophins but retain their responsiveness to CNTF, and that the application of CNTF induced these cells to withdraw from the mitotic cycle and morphologically differentiate into neurons.
Materials and Methods

Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee of the University of Vermont (Animal Welfare Assurance No. A3301-01; IACUC protocol No. 07-114). Every effort was made to minimize the suffering of the animals used.
Mice
Three homozygous breeding pairs of TH-MYCN mice [15] on the 129/SvJ background were obtained by material transfer from the Mouse Models of Human Cancers Consortium at the National Cancer Institute. Mice homozygous for the human MYCN gene were used for all experiments involving TH -MYCN tumor removal and growth in culture.
Immunostaining
Tumors were removed and immersion fixed overnight in Zamboni's fixative [4% (w/v) paraformaldehyde, 15% (v/v) picric acid in 0.1 M sodium phosphate buffer, pH 7.4]. The tumors were washed with PBS to remove the fixative and equilibrated in 15%, and then 30%, sucrose overnight at 4 ° C. Tissue sections of 20 μm thickness were cut using a Microm HM 560 cryostat (Thermo Scientific) and mounted on SuperFrost Plus slides (Fisher Scientific). The sections were postfixed for 15 min in Zamboni's fixative and placed into blocking solution [1× PBS consisting of 10% (v/v) heat-inactivated horse serum (Invitrogen), 0.5% Triton X-100 (Sigma), and 0.1% sodium azide (Fisher Scientific)] overnight at 4 ° C. They were stained with primary antibodies overnight at 4 ° C, followed by secondary antibodies for 3 h at room temperature (see below for the specific antibodies). Slides were then incubated in PBS plus Hoechst (1: 2,000; Invitrogen) for 5 min at room temperature to stain nuclei and mounted with Mowiol (EMD Millipore). After staining, the coverslips were mounted on slides with PermaFluor (Thermo Scientific) containing Hoechst (1: 2,000). Images were captured using a Nikon C1 confocal device mounted on a Nikon Eclipse E800 microscope with a 60× Plan Apo (NA 1.4) oil objective lens, E7-C1 software, and UV, Argon, and He/Ne lasers exciting at 408, 488, and 543 nm and emitting at 404, 500-530, and 555-615 nm, respectively.
Antibodies
The primary antibodies used were as follows: mouse anti-O4 (1: 1 of a hybridoma cell culture supernatant; a generous gift from Dr. Stephen Back, Oregon Health and Science University), rabbit anti-TrkA (1: 250; Abcam), mouse anti-p75 (1: 750; Promega), chicken anti-TH (1: 250; Aves), rabbit anti-Ki67 (1: 200; Novacastra), rabbit anti-CNTFRα (1: 30; a generous gift from Dr. Hermann Rohrer of the Max Planck Institute for Brain Research, Frankfurt, Germany), mouse anti-3A10 (neurofilament associated antigen, 1: 1; Development Studies Hybridoma Bank), and sheep anti-BrdU (1: 100; Biodesign). The secondary antibodies were donkey antirabbit Alexa 488 (1: 1,666; Invitrogen), donkey anti-mouse cy3 (1: 1,000; Jackson), donkey anti-rabbit cy3 (1: 1,000; Jackson), and donkey anti-goat Alexa 488 (1: 1,000; Invitrogen).
Cell Culture
All cells were grown at 37 ° C in 5% CO 2 . To obtain TH-MYCN tumor cells, tumors were removed from homozygous TH-MYCN mice at 35 days of age and mechanically dissociated by triturating in warm modified Puck's solution with glucose (a Ca 2+ -and Mg 2+ -free balanced salt solution) to obtain a single-cell suspension. Cells were then plated on coverslips (Fisher Scientific) coated with poly-D -lysine (0.5 mg/ml; Sigma) and laminin (0.02 mg/ml; purified in the Nishi laboratory from Engelbreth-Holm-Swarm tumors grown subcutaneously in C57Bl6 mice) at 50,000 cells/well in 24-well tissue culture plates (Falcon). They were grown in 20 U/ml penicillin, 20 mg/ml streptomycin, 2 m M L -glutamine, and 6 mg/ ml glucose in modified L15CO 2 424 vitrogen). Growth factors were added upon plating and consisted of the following: CNTF (5, 1, 0.5, and 0.25 ng/ml; Alomone), brainderived neurotrophic factor (BDNF; 10 ng/ml; R&D), leukemia inhibitory factor (LIF; 10 ng/ml; R&D), 7s NGF (1 μg/ml; Alomone), neurotrophin 3 (NT-3; 30 ng/ml; R&D), and glial cell-derived neurotrophic factor (GDNF; 10 ng/ml; PeproTech). For bromodeoxyuridine (BrdU) experiments, 10 μ M BrdU was added 2 h after plating and then washed out 24 h later.
Quantification of Process Outgrowth, Proliferation, and Neuronal Marker Expression
Following staining, process outgrowth and proliferation were quantified using a Nikon Eclipse E800 microscope connected to a computer equipped with StereoInvestigator and Neurolucida software (MBF Bioscience, Williston, Vt., USA) in the Center of Biomedical Research Excellence (COBRE) Molecular Cellular Core Facility. Briefly, after creating a defined counting area, the fractionator program of StereoInvestigator selects random views within that area in which the observer counts the number of morphologically intact cells to get an estimate of the total population. Process outgrowth was measured using Neurolucida. For each coverslip, 16 random views were selected in which to measure process length. All neurite processes falling within each of the 16 random fields of view were traced. Traced neurites in any given field of view came from multiple different tumor cells, many of which may fall out of the field of view given the extensive length of some processes (see online suppl. fig. 1 for example of tracings; for all online suppl. material, see www.karger.com/doi/10.1159/000365281). In order to derive the process length per cell value for each condition, the total process length from the 16 random views determined in Neurolucida was divided by the cell population as determined using StereoInvestigator. For the BrdU-Ki67 and TH-Ki67 studies, neurons stained above background were counted as positive for the indicated markers using the fractionator program of StereoInvestigator.
RNA Extraction and qPCR
For RNA extraction from TH-MYCN tumor cells, cells were lysed directly into TRI Reagent (Molecular Research Center) following dissociation, and RNA was isolated using the manufacturer's protocol. One microgram of RNA was transcribed to cDNA using superscript III (Invitrogen) and random hexamer priming (Invitrogen). cDNA was then diluted 1: 5, and CNTFRα and 18S RNA expression were quantified using FAM/BHQ-labeled primer/TaqMan probe mixes (ABI) and run on an ABI 7700 machine in the Molecular Cellular Core operated by the COBRE in the Neuroscience Department at the University of Vermont. Cycle threshold (Ct) values for the target gene (CNTFRα) were normalized to the control gene (18S) by using the equation 10,000/2 Ct (target) -CT (control) in accordance with ABI instructions. Mean values and standard deviations were calculated for each experiment. RNA samples from 4 superior cervical ganglion/tumor pairs from 4 separate mice were quantified.
Results
Tumor Development in TH-MYCN Mice
All the homozygous TH-MYCN mice examined formed palpable tumors by an average of 50 ± 1.0 days of postnatal (PN) age ( table 1 ) . Tumors were large, highly angiogenic, and formed predominantly in the abdomen, as in hemizygous mice [21] . In 2 of 14 mice, an asymmetrical enlargement of the superior cervical ganglion was also found. In 1 mouse, along with a tumor at or near the celiac ganglion, a separate tumor developing along the lower sympathetic chain was also observed. When examined at PN35, considerably smaller, yet readily identifiable, tumors could always be found at the site of the celiac/superior mesenteric complex, suggesting that virtually all of the larger abdominal tumors formed at this site. These tumors were approximately 3-5 times the size of the normal ganglion, well circumscribed, avascular, and homogeneously white-tan in appearance. As in the larger tumors harvested when palpable, tumor tissue at this earlier time point completely engulfed the normal ganglion, and less of the tissue was necrotic as often observed in larger tumors. These tumors could be readily differentiated from the normal ganglion.
While a minority of cells in sections from tumors harvested at PN35 express strong TH immunoreactivity ( fig. 1 a, d, g ), many of the cells express CNTFRα immu- fig. 1 b) . A large majority of cells in TH-MYCN tumors also stain strongly for Ki67, indicating a high rate of proliferation ( fig. 1 e, h ) and confirming that the tissue we isolated was tumor in origin rather than postmitotic ganglionic neurons. Additionally, the levels of CNTFRα mRNA expressed in tumors were not significantly different from those expressed in the superior cervical ganglion (32.8 ± 3.6 vs. 31.0 ± 6.0 arbitrary units; Student's t test; n = 4 independent assays; error = SEM).
In order to investigate the effects of CNTF, PN35 tumors were mechanically dissociated and placed in cell culture. Upon plating, tumor cells are small, round, and undifferentiated, and they lack cell processes. Occasional cells are TH positive ( fig. 2 a) , and 70% of the acutely isolated cells express CNTFRα ( fig. 2 b-d) . The percentage of CNTFRα-positive cells significantly increases after 3 days in culture, regardless of CNTF treatment ( fig. 2 d; p < 0.0001). TrkA immunoreactivity could not be detected. A 
CNTF Promotes the Differentiation of TH-MYCN Tumor Cells in vitro
Tumor cell cultures were then treated with BDNF (10 ng/ml), CNTF (5 ng/ml), GDNF (10 ng/ml), LIF (10 ng/ ml), 7s NGF (1 μg/ml), NT-3 (30 ng/ml), and a combination of 7s NGF (1 μg/ml) and NT-3 (30 ng/ml). To measure differentiation, cultures were fixed and stained with mAb 3A10, which recognizes a neurofilament-associated antigen that is neuron specific [22] . The lengths of the 3A10-positive neurites were then quantified. After 4 days in vitro, treatment with CNTF and LIF, but not other growth factors, promotes approximately a 4-fold increase in process outgrowth ( fig. 3 a, gray bars; p < 0.01) as well as a 15% reduction in proliferation, as measured by Ki67 staining ( fig. 3 a, black bars; p < 0.05). After only 3 days in vitro, CNTF-treated tumor cells are visibly more differentiated than untreated cells ( fig. 3 b, c ; online suppl. fig. 1 ). While both CNTF and LIF signaling involves the LIFRβ and GP130 receptor signaling subunits, CNTF signaling requires the additional presence of a CNTFRα subunit, a glycosyl-phosphoinositide-linked coreceptor commonly expressed in cells of both the peripheral and central nervous system [23] , which binds CNTF [24] . Therefore, the differentiating effects of CNTF rather than of LIF on TH-MYCN tumor cells were further investigated.
When quantifying the CNTF-induced process outgrowth and inhibition of proliferation after 1, 2, and 3 days of CNTF treatment, these CNTF-induced effects reach significance after 3 days of treatment ( fig. 4 a, c; p < 0.0001). No significant changes in cell number are observed over the time course of CNTF treatment ( fig. 4 e) . The effects of CNTF are concentration dependent (p < 0.01), with an EC 50 of approximately 0.4 ng/ml for the effects on neurite outgrowth ( fig. 4 b) and proliferation ( fig. 4 d) , similar to the EC 50 observed in the CNTF-induced decreases in proliferation in embryonic chicken sympathetic neurons [25] . Consistent with the time course experiments, there was no concentration-dependent effect of CNTF on cell number ( fig. 4 f) .
CNTF Promotes the Withdrawal of Proliferating Cells from the Cell Cycle
To determine whether CNTF induces actively dividing cells to withdraw from the cell cycle, we incubated cells in BrdU (10 μ M ) to label the DNA of all dividing cells, and cells were treated with or without CNTF. After 24 h, the BrdU was washed out, and the media and CNTF were re- There is a significant increase in CNTFRα expression from day 0 to day 3 ( * * * * p < 0.0001, analysis of variance; n = 4). However, 3 days of CNTF treatment has no effect on CNTFRα expression. Error bars = SEM. That is, cells that were originally dividing during day 1 in cell culture, and therefore were marked by BrdU, lost Ki67 immunoreactivity if treated with CNTF, indicating that formerly proliferating cells had withdrawn from the cell cycle. We also examined TH expression in combination with Ki67 in tumor cells after 2 h in culture ('acutely isolated') and in cells treated with saline or CNTF for 3 days. Overall, the total cell numbers in these cultures do not significantly differ ( fig. 6 a) . However, there is a significant increase in the percentage of cells that are immunoreactive for TH, but not Ki67, in cells treated with CNTF compared with both acutely isolated and untreated tumor cells ( fig. 6 b) . Additionally, in cells treated with CNTF compared with untreated tumor cells, there is a significant decrease in the percentage of cells that are immunoreactive for both TH and Ki67, and in the percentage of cells that are immunoreactive for Ki67 but not TH. Therefore, the percentage of cells that were TH positive and Ki67 negative (and, hence, nonproliferating) increased dramatically with CNTF ( fig. 6 b) , suggesting that CNTF promotes withdrawal from the cell cycle and induces the expression of TH.
Discussion
The principal finding of this study is that the growth factor CNTF induces cell cycle withdrawal and promotes the differentiation of TH-MYCN tumor cells into an early neuronal phenotype that includes the expression of Growth factor effects on the process outgrowth and proliferation of TH-MYCN tumor cells in culture. a CNTF (5 ng/ml) and LIF (10 ng/ml), which both activate the CNTF receptor, significantly increase process outgrowth (gray bars; * * p < 0.01, analysis of variance; n = 5) and inhibit proliferation (black bars; # p < 0.05, analysis of variance; n = 5) in tumor cells derived from TH-MYCN mice after 4 days in vitro compared with control, BDNF (10 ng/ml), GDNF (10 ng/ml), NGF (1 μg/ml), NT-3 (30 ng/ml), and NGF and NT-3. Error bars = SEM. b , c ×60 confocal images demonstrating CNTF-induced process outgrowth after 3 days in TH-MYCN tumor cells stained for 3A10, a neurofilament-associated antigen. Image brightness enhanced to highlight cell processes. Calibration bar = 100 μm.
neurofilament-associated protein, extensive neurite outgrowth, and the expression of TH. Virtually all cells isolated from the tumor were Ki67 positive, indicating that they were proliferating, and the majority of these cells expressed CNTFRα. Up to 40% of the cells in culture responded to CNTF, suggesting that CNTF responsiveness is not limited to a minor population of neurons hidden in the tumor. These effects were not observed with other neurotrophic factors known to promote the survival of sympathetic or sensory neurons (BDNF, NGF, NT-3, or GDNF). Taken together, our data suggest that a further understanding of the molecular mechanisms involved in neuropoietic cytokine signaling could provide a potential mechanism for promoting differentiation in neuroblastoma.
The effect of CNTF we observed on dividing TH-MYCN cells is similar to the effect of CNTF on proliferating, cultured embryonic day (E)7 chicken sympathetic neuroblasts [25] . CNTF causes an approximately 30% reduction in the number of proliferating cells in both embryonic sympathetic neurons and TH-MYCN tumor cells. In addition, NGF and BDNF have no effect on TH-MYCN what we observe in this study, the MYCN -amplified neuroblastoma cell lines LA-N-2 and SK-N-BE respond to CNTF treatment with enhanced neurite outgrowth, marked by an increased number of tumor cells with neurites, and increased neurite length [28] . However, in the neuroblastoma cell line SY5Y, from which the CNTFRα receptor was originally cloned due to its abundant expression in these cells [29] , treatment with CNTF activates the JAK-STAT pathways downstream of CNTFRα but does not cause tumor cell differentiation [28, 30] , perhaps due to a disruption of downstream pathways leading to differentiation. Furthermore, although CNTF treatment induces the expression of the neurotrophin receptor TrkA in both GOTO and HTLA230 neuroblastoma cell lines, subsequent treatment with the TrkA ligand NGF results in proliferation in GOTO cells but differentiation in HTLA230 cells [31] .
In the TH-MYCN mouse model, the overexpression of MYCN in sympathoadrenal neural progenitors likely causes cells to ignore cell cycle checkpoints and allows an accumulation of DNA mutations, leading to a transformed phenotype. While N-myc was first identified in neuroblastoma [32] , it is now well known that this transcription factor is selectively expressed in virtually all dividing neural progenitors [33] . When cells commence neural differentiation, N-myc is downregulated, and the cells undergo terminal withdrawal from mitosis. If N-myc continues to be expressed at high levels, continued proliferation likely leads to a transformed phenotype. Such a process would seem to lead to tumors with heterogeneous phenotypes; yet, our studies have shown that all tumors formed in this mouse model contain cells that respond to CNTF but not to other neurotrophic factors typical of sympathetic neurons (NT-3, NGF, and GDNF). Thus, MYCN overexpression differentially affects responsiveness to neurotrophic molecules rather than causing a complete dedifferentiation of the progenitors.
Based on our studies, we suggest that MYCN overexpression results in a propagation of an immature, dividing sympathoadrenal phenotype. This is supported by the observation that MYCN promotes the expansion of Phox2B-positive neuronal progenitors in this mouse model [17] . We suggest that a subset of MYCN-amplified human neuroblastoma tumors may also be the same and retain the capacity to respond to CNTF. In fact, neuroblastoma patients whose tumors express high mRNA levels of either CNTF or CNTFRα have improved survival over patients whose tumors have a low expression of the two transcripts (http://home.ccr.cancer.gov/oncology/ oncogenomics/). There is no significant difference between the 3 culture conditions (one-way analysis of variance; n = 4 cultures for each condition). b Percent of total cells from the condition described in a that are TH and Ki67 positive. Percentages were analyzed by two-way analysis of variance and pair-wise comparisons were done using Tukey's post hoc test. * * * p < 0.001, * * * * p < 0.0001. Error bars = SEM.
